StreetInsider.com News Articles

Lundbeck announces headline results from Phase IV THRIVE trial evaluating VYEPTI® (eptinezumab) following inadequate response to prior CGRP-targeting preventive therapy

Thu, 01 Oct 2026 02:17:00 -0400

Primary endpoint analysis of the clinical Phase IV THRIVE trial showed that 60% of participants reported being 'much improved' or 'very much improved' following treatment with eptinezumab
Results provide prospective clinical data on the use of eptinezumab in adults with migraine following inadequate response to one prior

Lundbeck announces headline results from Phase IV THRIVE trial evaluating VYEPTI® (eptinezumab) following inadequate response to prior CGRP-targeting preventive therapy

Thu, 01 Oct 2026 02:17:00 -0400

Primary endpoint analysis of the clinical Phase IV THRIVE trial showed that 60% of participants reported being 'much improved' or 'very much improved' following treatment with eptinezumab
Results provide prospective clinical data on the use of eptinezumab in adults with migraine following inadequate response to one prior

Lundbeck announces headline results from Phase IV THRIVE trial evaluating VYEPTI® (eptinezumab) following inadequate response to prior CGRP-targeting preventive therapy

Thu, 01 Oct 2026 02:17:00 -0400

Primary endpoint analysis of the clinical Phase IV THRIVE trial showed that 60% of participants reported being 'much improved' or 'very much improved' following treatment with eptinezumab
Results provide prospective clinical data on the use of eptinezumab in adults with migraine following inadequate response to one prior

Lundbeck announces headline results from Phase IV THRIVE trial evaluating VYEPTI® (eptinezumab) following inadequate response to prior CGRP-targeting preventive therapy

Thu, 01 Oct 2026 02:17:00 -0400

Primary endpoint analysis of the clinical Phase IV THRIVE trial showed that 60% of participants reported being 'much improved' or 'very much improved' following treatment with eptinezumab
Results provide prospective clinical data on the use of eptinezumab in adults with migraine following inadequate response to one prior

Lundbeck announces headline results from Phase IV THRIVE trial evaluating VYEPTI® (eptinezumab) following inadequate response to prior CGRP-targeting preventive therapy

Thu, 01 Oct 2026 02:17:00 -0400

Primary endpoint analysis of the clinical Phase IV THRIVE trial showed that 60% of participants reported being 'much improved' or 'very much improved' following treatment with eptinezumab
Results provide prospective clinical data on the use of eptinezumab in adults with migraine following inadequate response to one prior

Lundbeck announces headline results from Phase IV THRIVE trial evaluating VYEPTI® (eptinezumab) following inadequate response to prior CGRP-targeting preventive therapy

Thu, 01 Oct 2026 02:17:00 -0400

Primary endpoint analysis of the clinical Phase IV THRIVE trial showed that 60% of participants reported being 'much improved' or 'very much improved' following treatment with eptinezumab
Results provide prospective clinical data on the use of eptinezumab in adults with migraine following inadequate response to one prior

Lundbeck announces last patient randomized in DEEp SEA, a Phase III trial of bexicaserin in Dravet syndrome

Tue, 15 Sep 2026 03:26:00 -0400

DEEp SEA is a global Phase III trial evaluating efficacy, safety and tolerability of the investigational molecule bexicaserin in children and adults with Dravet syndrome¹
Completion of randomization marks another important milestone for the global Phase III DEEp program, with randomization now complete in both pivotal trials

Lundbeck announces last patient randomized in DEEp SEA, a Phase III trial of bexicaserin in Dravet syndrome

Tue, 15 Sep 2026 03:26:00 -0400

DEEp SEA is a global Phase III trial evaluating efficacy, safety and tolerability of the investigational molecule bexicaserin in children and adults with Dravet syndrome¹
Completion of randomization marks another important milestone for the global Phase III DEEp program, with randomization now complete in both pivotal trials

Lundbeck announces last patient randomized in DEEp SEA, a Phase III trial of bexicaserin in Dravet syndrome

Tue, 15 Sep 2026 03:26:00 -0400

DEEp SEA is a global Phase III trial evaluating efficacy, safety and tolerability of the investigational molecule bexicaserin in children and adults with Dravet syndrome¹
Completion of randomization marks another important milestone for the global Phase III DEEp program, with randomization now complete in both pivotal trials

Lundbeck announces last patient randomized in DEEp SEA, a Phase III trial of bexicaserin in Dravet syndrome

Tue, 15 Sep 2026 03:26:00 -0400

DEEp SEA is a global Phase III trial evaluating efficacy, safety and tolerability of the investigational molecule bexicaserin in children and adults with Dravet syndrome¹
Completion of randomization marks another important milestone for the global Phase III DEEp program, with randomization now complete in both pivotal trials

Lundbeck announces last patient randomized in DEEp SEA, a Phase III trial of bexicaserin in Dravet syndrome

Tue, 15 Sep 2026 03:26:00 -0400

DEEp SEA is a global Phase III trial evaluating efficacy, safety and tolerability of the investigational molecule bexicaserin in children and adults with Dravet syndrome¹
Completion of randomization marks another important milestone for the global Phase III DEEp program, with randomization now complete in both pivotal trials

Lundbeck announces last patient randomized in DEEp SEA, a Phase III trial of bexicaserin in Dravet syndrome

Tue, 15 Sep 2026 03:26:00 -0400

DEEp SEA is a global Phase III trial evaluating efficacy, safety and tolerability of the investigational molecule bexicaserin in children and adults with Dravet syndrome¹
Completion of randomization marks another important milestone for the global Phase III DEEp program, with randomization now complete in both pivotal trials

European Commission grants orphan designation for Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for Cushing's syndrome of endogenous origin

Mon, 24 Aug 2026 05:33:00 -0400

The European Commission has granted orphan designation for asedebart (Lu AG13909), Lundbeck's novel investigational anti-ACTH monoclonal antibody, for the treatment of Cushing's syndrome of endogenous origin
Cushing's syndrome of endogenous origin is a rare endocrine disorder driven in most cases by excess adrenocorticotropic hormone, or ACTH, leading to chronic cortisol excess and substantial disease burden with current treatment options often limited by suboptimal disease control and treatment-related complications³
Proof-of-concept trial currently ongoing to evaluate efficacy and safety in Cushing's disease (CD)

VALBY, Denmark, Aug. 24, 2026 /PRNewswire/ -- Lundbeck today announced that the

European Commission grants orphan designation for Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for Cushing's syndrome of endogenous origin

Mon, 24 Aug 2026 05:33:00 -0400

The European Commission has granted orphan designation for asedebart (Lu AG13909), Lundbeck's novel investigational anti-ACTH monoclonal antibody, for the treatment of Cushing's syndrome of endogenous origin
Cushing's syndrome of endogenous origin is a rare endocrine disorder driven in most cases by excess adrenocorticotropic hormone, or ACTH, leading to chronic cortisol excess and substantial disease burden with current treatment options often limited by suboptimal disease control and treatment-related complications³
Proof-of-concept trial currently ongoing to evaluate efficacy and safety in Cushing's disease (CD)

VALBY, Denmark, Aug. 24, 2026 /PRNewswire/ -- Lundbeck today announced that the

European Commission grants orphan designation for Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for Cushing's syndrome of endogenous origin

Mon, 24 Aug 2026 05:33:00 -0400

The European Commission has granted orphan designation for asedebart (Lu AG13909), Lundbeck's novel investigational anti-ACTH monoclonal antibody, for the treatment of Cushing's syndrome of endogenous origin
Cushing's syndrome of endogenous origin is a rare endocrine disorder driven in most cases by excess adrenocorticotropic hormone, or ACTH, leading to chronic cortisol excess and substantial disease burden with current treatment options often limited by suboptimal disease control and treatment-related complications³
Proof-of-concept trial currently ongoing to evaluate efficacy and safety in Cushing's disease (CD)

VALBY, Denmark, Aug. 24, 2026 /PRNewswire/ -- Lundbeck today announced that the

European Commission grants orphan designation for Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for Cushing's syndrome of endogenous origin

Mon, 24 Aug 2026 05:33:00 -0400

The European Commission has granted orphan designation for asedebart (Lu AG13909), Lundbeck's novel investigational anti-ACTH monoclonal antibody, for the treatment of Cushing's syndrome of endogenous origin
Cushing's syndrome of endogenous origin is a rare endocrine disorder driven in most cases by excess adrenocorticotropic hormone, or ACTH, leading to chronic cortisol excess and substantial disease burden with current treatment options often limited by suboptimal disease control and treatment-related complications³
Proof-of-concept trial currently ongoing to evaluate efficacy and safety in Cushing's disease (CD)

VALBY, Denmark, Aug. 24, 2026 /PRNewswire/ -- Lundbeck today announced that the

European Commission grants orphan designation for Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for Cushing's syndrome of endogenous origin

Mon, 24 Aug 2026 05:33:00 -0400

The European Commission has granted orphan designation for asedebart (Lu AG13909), Lundbeck's novel investigational anti-ACTH monoclonal antibody, for the treatment of Cushing's syndrome of endogenous origin
Cushing's syndrome of endogenous origin is a rare endocrine disorder driven in most cases by excess adrenocorticotropic hormone, or ACTH, leading to chronic cortisol excess and substantial disease burden with current treatment options often limited by suboptimal disease control and treatment-related complications³
Proof-of-concept trial currently ongoing to evaluate efficacy and safety in Cushing's disease (CD)

VALBY, Denmark, Aug. 24, 2026 /PRNewswire/ -- Lundbeck today announced that the

European Commission grants orphan designation for Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for Cushing's syndrome of endogenous origin

Mon, 24 Aug 2026 05:33:00 -0400

The European Commission has granted orphan designation for asedebart (Lu AG13909), Lundbeck's novel investigational anti-ACTH monoclonal antibody, for the treatment of Cushing's syndrome of endogenous origin
Cushing's syndrome of endogenous origin is a rare endocrine disorder driven in most cases by excess adrenocorticotropic hormone, or ACTH, leading to chronic cortisol excess and substantial disease burden with current treatment options often limited by suboptimal disease control and treatment-related complications³
Proof-of-concept trial currently ongoing to evaluate efficacy and safety in Cushing's disease (CD)

VALBY, Denmark, Aug. 24, 2026 /PRNewswire/ -- Lundbeck today announced that the

European Commission grants orphan designation for Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for Cushing's syndrome of endogenous origin

Mon, 24 Aug 2026 05:33:00 -0400

The European Commission has granted orphan designation for asedebart (Lu AG13909), Lundbeck's novel investigational anti-ACTH monoclonal antibody, for the treatment of Cushing's syndrome of endogenous origin
Cushing's syndrome of endogenous origin is a rare endocrine disorder driven in most cases by excess adrenocorticotropic hormone, or ACTH, leading to chronic cortisol excess and substantial disease burden with current treatment options often limited by suboptimal disease control and treatment-related complications³
Proof-of-concept trial currently ongoing to evaluate efficacy and safety in Cushing's disease (CD)

VALBY, Denmark, Aug. 24, 2026 /PRNewswire/ -- Lundbeck today announced that the

European Commission grants orphan designation for Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for Cushing's syndrome of endogenous origin

Mon, 24 Aug 2026 05:33:00 -0400

The European Commission has granted orphan designation for asedebart (Lu AG13909), Lundbeck's novel investigational anti-ACTH monoclonal antibody, for the treatment of Cushing's syndrome of endogenous origin
Cushing's syndrome of endogenous origin is a rare endocrine disorder driven in most cases by excess adrenocorticotropic hormone, or ACTH, leading to chronic cortisol excess and substantial disease burden with current treatment options often limited by suboptimal disease control and treatment-related complications³
Proof-of-concept trial currently ongoing to evaluate efficacy and safety in Cushing's disease (CD)

VALBY, Denmark, Aug. 24, 2026 /PRNewswire/ -- Lundbeck today announced that the

European Commission grants orphan designation for Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for Cushing's syndrome of endogenous origin

Mon, 24 Aug 2026 05:33:00 -0400

The European Commission has granted orphan designation for asedebart (Lu AG13909), Lundbeck's novel investigational anti-ACTH monoclonal antibody, for the treatment of Cushing's syndrome of endogenous origin
Cushing's syndrome of endogenous origin is a rare endocrine disorder driven in most cases by excess adrenocorticotropic hormone, or ACTH, leading to chronic cortisol excess and substantial disease burden with current treatment options often limited by suboptimal disease control and treatment-related complications³
Proof-of-concept trial currently ongoing to evaluate efficacy and safety in Cushing's disease (CD)

VALBY, Denmark, Aug. 24, 2026 /PRNewswire/ -- Lundbeck today announced that the

European Commission grants orphan designation for Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for Cushing's syndrome of endogenous origin

Mon, 24 Aug 2026 05:33:00 -0400

The European Commission has granted orphan designation for asedebart (Lu AG13909), Lundbeck's novel investigational anti-ACTH monoclonal antibody, for the treatment of Cushing's syndrome of endogenous origin
Cushing's syndrome of endogenous origin is a rare endocrine disorder driven in most cases by excess adrenocorticotropic hormone, or ACTH, leading to chronic cortisol excess and substantial disease burden with current treatment options often limited by suboptimal disease control and treatment-related complications³
Proof-of-concept trial currently ongoing to evaluate efficacy and safety in Cushing's disease (CD)

VALBY, Denmark, Aug. 24, 2026 /PRNewswire/ -- Lundbeck today announced that the

European Commission grants orphan designation for Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for Cushing's syndrome of endogenous origin

Mon, 24 Aug 2026 05:33:00 -0400

The European Commission has granted orphan designation for asedebart (Lu AG13909), Lundbeck's novel investigational anti-ACTH monoclonal antibody, for the treatment of Cushing's syndrome of endogenous origin
Cushing's syndrome of endogenous origin is a rare endocrine disorder driven in most cases by excess adrenocorticotropic hormone, or ACTH, leading to chronic cortisol excess and substantial disease burden with current treatment options often limited by suboptimal disease control and treatment-related complications³
Proof-of-concept trial currently ongoing to evaluate efficacy and safety in Cushing's disease (CD)

VALBY, Denmark, Aug. 24, 2026 /PRNewswire/ -- Lundbeck today announced that the

European Commission grants orphan designation for Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for Cushing's syndrome of endogenous origin

Mon, 24 Aug 2026 05:33:00 -0400

The European Commission has granted orphan designation for asedebart (Lu AG13909), Lundbeck's novel investigational anti-ACTH monoclonal antibody, for the treatment of Cushing's syndrome of endogenous origin
Cushing's syndrome of endogenous origin is a rare endocrine disorder driven in most cases by excess adrenocorticotropic hormone, or ACTH, leading to chronic cortisol excess and substantial disease burden with current treatment options often limited by suboptimal disease control and treatment-related complications³
Proof-of-concept trial currently ongoing to evaluate efficacy and safety in Cushing's disease (CD)

VALBY, Denmark, Aug. 24, 2026 /PRNewswire/ -- Lundbeck today announced that the

European Commission grants orphan designation for Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for Cushing's syndrome of endogenous origin

Mon, 24 Aug 2026 05:33:00 -0400

The European Commission has granted orphan designation for asedebart (Lu AG13909), Lundbeck's novel investigational anti-ACTH monoclonal antibody, for the treatment of Cushing's syndrome of endogenous origin
Cushing's syndrome of endogenous origin is a rare endocrine disorder driven in most cases by excess adrenocorticotropic hormone, or ACTH, leading to chronic cortisol excess and substantial disease burden with current treatment options often limited by suboptimal disease control and treatment-related complications³
Proof-of-concept trial currently ongoing to evaluate efficacy and safety in Cushing's disease (CD)

VALBY, Denmark, Aug. 24, 2026 /PRNewswire/ -- Lundbeck today announced that the